Report cover image

Global Cell Signaling Market - 2024-2031

Publisher DataM Intelligence 4Market Research LLP
Published Jun 18, 2024
Length 186 Pages
SKU # DTAM18904533

Description

Global Cell Signaling Market - 2024-2031


Global Cell Signaling Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Cell signaling is the process of responding to external substances through signaling molecules on its surface and inside. Chemical substances like hormones, neurotransmitters, and growth factors bind to specific protein receptors, producing cell responses like division or death. Cell signaling is crucial for normal cell growth and function, and abnormal signaling molecules may lead to cancer also known as signal transduction.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of chronic diseases

The rise in the prevalence of chronic diseases is a significant driver of the cell signaling market. Chronic diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders require an in-depth understanding of cellular mechanisms and signaling pathways for the development of effective treatments.

For instance, according to CDC 2024, the US has 129 million people with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Five of the top 10 leading causes of death in the US are associated with preventable and treatable chronic diseases.

Over the past two decades, prevalence has steadily increased, and this trend is expected to continue. An increasing proportion of Americans are dealing with multiple chronic conditions, with 42% having two or more and 12% having at least five. Chronic diseases also significantly impact the US healthcare system, with 90% of annual $4.1 trillion expenditure attributed to managing and treating these conditions.



Ethical issues related to embryonic stem cell signaling research



Stem cell research holds great promise for understanding human development and differentiation, and for developing new treatments for diseases like diabetes, spinal cord injury, Parkinson's disease, and myocardial infarction. However, ethical and political controversies arise during the derivation of pluripotent stem cell lines from oocytes and embryos, including consent to donate materials, early clinical trials of therapies, and oversight of research. These issues are hindering market growth in embryonic stem cell signaling research.



For more details on this report – Request for Sample

Segment Analysis

The global cell signaling market is segmented based on product type, signaling type, pathway, technology, end-user and region.

The consumables from the product type segment accounted for approximately 42.3% of the cell signaling market share

The consumables from the product type segment accounted for approximately 42.3%. The consumables segment is expected to grow due to factors like, the expanding number of advances in genomes and proteomics, as well as the growing emphasis on customized medicine and targeted therapies, are accelerating this segment's growth rate.

Growing government and private sector funding of cell-based research is predicted to propel the global cell signaling industry forward. For instance according to data from the National Institutes of Health (NIH) portal, an estimated USD 45 billion was provided for stem cell research in fiscal year 2021. Similar increases in funding grants for research on embryonic stem cells & induced pluripotent stem cells were observed in March 2020.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the local presence of a substantial number of key players such as Thermo Fisher Scientific, Merck KGaA, and Cell Signaling Technology Inc., among others, coupled with an upsurge in research and development spending by key players to develop innovative and advanced products, are attributed for the regional cell signaling industry growth.

For instance, in September 2023, Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, announced the launch of its SignalStar Multiplex IHC technology, a revolutionary new tool for spatial biology research using mid-plex, high-throughput immunohistochemistry (IHC) assays.

Market Segmentation

By Product Type
• Consumables
• Instruments
• Reagent and Kits

By Signaling Type
• Endocrine Signaling
• Paracrine Signaling
• Autocrine Signaling
• Synaptic Signaling
• Others

By Pathway
• AKT Signaling Pathway
• AMPK Signaling Pathway
• ErbB/HER Signaling Pathway
• Others

By Technology
• Flow Cytometry
• Mass Spectrometry
• Western Blotting
• ELISA
• Others

By End User
• Hospitals
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutions
• Contract Research Organizations (CROs)
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fischer Scientific Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen NV, Beijing Boshumei Biotechnology Co., Ltd among others.

Key Developments

 In February 2023, Bio-Techne Corporation and Cell Signaling Technology (CST) announced the addition of Simple Western validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signaling pathways on a trusted and validated platform.

 In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced a partnership to help increase local availability of next-generation sequencing (NGS)-based screening for patients with lung & breast cancer in more than 30 countries across Latin America, the Middle East, Africa, and Asia where advanced genomic testing was previously limited or unavailable.



Why Purchase the Report??
• To visualize the global cell signaling market segmentation based on product type, signaling type, pathway, technology, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the cell signaling market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cell signaling market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

186 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Signaling Type
3.3. Snippet by Pathway
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of chronic diseases
4.1.1.2. Rise of technological advancement in cell-based signaling research
4.1.2. Restraints
4.1.2.1. Ethical issues related to embryonic stem cell signaling research
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Consumables *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Instruments
7.4. Reagent and Kits
8. By Signaling Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signaling Type
8.1.2. Market Attractiveness Index, By Signaling Type
8.2. Endocrine Signaling*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Paracrine Signaling
8.4. Autocrine Signaling
8.5. Synaptic Signaling
8.6. Others
9. By Pathway
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathway
9.2. Market Attractiveness Index, By Pathway
9.3. AKT Signaling Pathway*
9.3.1. Introduction
9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.4. AMPK Signaling Pathway
9.5. ErbB/HER Signaling Pathway
9.6. Others
10. By Technology
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.1.2. Market Attractiveness Index, By Technology
10.2. Flow Cytometry*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Mass Spectrometry
10.4. Western Blotting
10.5. ELISA
10.6. Others
11. By End User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Pharmaceutical and Biotechnology Companies
11.4. Academic and Research Institutions
11.5. Contract Research Organizations (CROs)
11.6. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signaling Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathway
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Technology
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signaling Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathway
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Technology
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signaling Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathway
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Technology
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signaling Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathway
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Technology
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. South Korea
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signaling Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathway
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Technology
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Thermo Fisher Scientific, Inc*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Becton, Dickinson and Company
14.3. Bio-Rad Laboratories Inc
14.4. Bio-Techne Corporation
14.5. Cell Signaling Technology Inc
14.6. Merck KGaA
14.7. PerkinElmer Inc
14.8. Promega Corporation
14.9. Qiagen NV
14.10. Beijing Boshumei Biotechnology Co., Ltd
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us